Life Science Investing Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma
Life Science Investing Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology Immuno-Oncology Congress 2025
Life Science Investing ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
Life Science Investing Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
Life Science Investing Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Juggernaut Confirms District Scale Gold-Rich System on Big One Property Measuring 22 km2 with Assays up to 263.70 g/t AuEq that is Drill Ready, Golden Triangle, B.C.
